A20 (TNFAIP3) Alleviates CVB3-induced Myocarditis Via Inhibiting NF-κB Signaling

Overview

Journal PLoS One

Specialties General Medicine
Science

Date 2012 Oct 3

PMID 23029542

Citations 31

Authors

Jun Gui

Yan Yue

Ruizhen Chen

Wei Xu

Sidong Xiong

Affiliations

Soon will be listed here.

Abstract

Background: Viral myocarditis, which is most prevalently caused by Coxsackievirus B3 (CVB3) infection, is a serious clinical condition characterized by cardiac inflammation. However, efficient therapies targeting inflammation are still lacking and much needed. A20, also known as tumor necrosis factor alpha induced protein 3 (TNFAIP3) is a key negative regulator of inflammation. But whether A20 may affect cardiac inflammation during acute viral myocarditis remains to be elucidated. The aim of this study was to investigate the potential protective effect of A20 on CVB3-induced myocarditis.

Methodology/principal Findings: Mice were intraperitoneally inoculated with CVB3 to establish acute viral myocarditis model. We found that the expression of pro-inflammatory cytokines, including tumor necrosis factor-α (TNF-α), interleukin (IL)-1β, IL-6 and monocyte chemotactic protein-1 (MCP-1) were markedly and persistently increased during the progression of CVB3-induced myocarditis, and positively correlated with the disease severity. Notably, intravenous injection in vivo with adenovirus expressed A20 (Ad-A20) remarkably reduced CVB3-induced pro-inflammatory cytokines production and alleviated the severity of myocarditis. Further, we observed that nuclear factor-kappaB (NF-κB) signaling which mediates inflammatory response was significantly inhibited in CVB3-infected mice with Ad-A20 treatment. Finally, we revealed that A20 was required to inhibit CVB3-induced NF-κB signaling by restricting TNF receptor associated factor 6 (TRAF6) ubiquitylation.

Conclusion/significance: This study demonstrates the protective role of A20 against CVB3-induced myocarditis, which may provide a new therapeutic strategy for the treatment of viral myocarditis.

Citing Articles

Cardiac-specific ITCH overexpression ameliorates septic cardiomyopathy inhibition of the NF-κB signaling pathway.

Saito Y, Otaki Y, Watanabe T, Tachibana S, Sato J, Kobayashi Y J Mol Cell Cardiol Plus. 2025; 2():100018.

PMID: 39802494 PMC: 11708253. DOI: 10.1016/j.jmccpl.2022.100018.

Roles of inflammasomes in viral myocarditis.

Xu J, Zhou Z, Zheng Y, Yang S, Huang K, Li H Front Cell Infect Microbiol. 2023; 13:1149911.

PMID: 37256114 PMC: 10225676. DOI: 10.3389/fcimb.2023.1149911.

Research on the Mechanism of HRP Relieving IPEC-J2 Cells Immunological Stress Based on Transcriptome Sequencing Analysis.

Li M, Chen L, Zhao Y, Sun H, Zhao L Front Nutr. 2022; 9:944390.

PMID: 35911118 PMC: 9336541. DOI: 10.3389/fnut.2022.944390.

A20 (TNFAIP3) alleviates viral myocarditis through ADAR1/miR-1a-3p-dependent regulation.

Li B, Xie X BMC Cardiovasc Disord. 2022; 22(1):10.

PMID: 35034631 PMC: 8762865. DOI: 10.1186/s12872-021-02438-z.

Knockout of the Cannabinoid Receptor 2 Gene Promotes Inflammation and Hepatic Stellate Cell Activation by Promoting A20/Nuclear Factor-κB (NF-κB) Expression in Mice with Carbon Tetrachloride-Induced Liver Fibrosis.

Long C, Xie N, Shu Y, Wu Y, He P, Zhou Y Med Sci Monit. 2021; 27:e931236.

PMID: 34413280 PMC: 8409143. DOI: 10.12659/MSM.931236.

References

Maelfait J, Roose K, Bogaert P, Sze M, Saelens X, Pasparakis M . A20 (Tnfaip3) deficiency in myeloid cells protects against influenza A virus infection. PLoS Pathog. 2012; 8(3):e1002570. PMC: 3291650. DOI: 10.1371/journal.ppat.1002570. View

Shen Y, Xu W, Chu Y, Wang Y, Liu Q, Xiong S . Coxsackievirus group B type 3 infection upregulates expression of monocyte chemoattractant protein 1 in cardiac myocytes, which leads to enhanced migration of mononuclear cells in viral myocarditis. J Virol. 2004; 78(22):12548-56. PMC: 525049. DOI: 10.1128/JVI.78.22.12548-12556.2004. View

Bonci D, Cittadini A, Latronico M, Borello U, Aycock J, Drusco A . 'Advanced' generation lentiviruses as efficient vectors for cardiomyocyte gene transduction in vitro and in vivo. Gene Ther. 2003; 10(8):630-6. DOI: 10.1038/sj.gt.3301936. View

Wertz I, ORourke K, Zhou H, Eby M, Aravind L, Seshagiri S . De-ubiquitination and ubiquitin ligase domains of A20 downregulate NF-kappaB signalling. Nature. 2004; 430(7000):694-9. DOI: 10.1038/nature02794. View

Li H, Zhuo M, Wang D, Wang A, Cai H, Sun L . Targeted cardiac overexpression of A20 improves left ventricular performance and reduces compensatory hypertrophy after myocardial infarction. Circulation. 2007; 115(14):1885-94. DOI: 10.1161/CIRCULATIONAHA.106.656835. View

Fan Y, Weifeng W, Yuluan Y, Qing K, Yu P, Yanlan H . Treatment with a neutralizing anti-murine interleukin-17 antibody after the onset of coxsackievirus b3-induced viral myocarditis reduces myocardium inflammation. Virol J. 2011; 8:17. PMC: 3032710. DOI: 10.1186/1743-422X-8-17. View

Yue Y, Gui J, Ai W, Xu W, Xiong S . Direct gene transfer with IP-10 mutant ameliorates mouse CVB3-induced myocarditis by blunting Th1 immune responses. PLoS One. 2011; 6(3):e18186. PMC: 3062568. DOI: 10.1371/journal.pone.0018186. View

Song X, Evel-Kabler K, Shen L, Rollins L, Huang X, Chen S . A20 is an antigen presentation attenuator, and its inhibition overcomes regulatory T cell-mediated suppression. Nat Med. 2008; 14(3):258-65. PMC: 3684168. DOI: 10.1038/nm1721. View

Lee E, Boone D, Chai S, Libby S, Chien M, Lodolce J . Failure to regulate TNF-induced NF-kappaB and cell death responses in A20-deficient mice. Science. 2000; 289(5488):2350-4. PMC: 3582399. DOI: 10.1126/science.289.5488.2350. View

10.

Levine B, Kalman J, Mayer L, Fillit H, Packer M . Elevated circulating levels of tumor necrosis factor in severe chronic heart failure. N Engl J Med. 1990; 323(4):236-41. DOI: 10.1056/NEJM199007263230405. View

11.

Boone D, Turer E, Lee E, Ahmad R, Wheeler M, Tsui C . The ubiquitin-modifying enzyme A20 is required for termination of Toll-like receptor responses. Nat Immunol. 2004; 5(10):1052-60. DOI: 10.1038/ni1110. View

12.

Onose A, Hashimoto S, Hayashi S, Maruoka S, Kumasawa F, Mizumura K . An inhibitory effect of A20 on NF-kappaB activation in airway epithelium upon influenza virus infection. Eur J Pharmacol. 2006; 541(3):198-204. DOI: 10.1016/j.ejphar.2006.03.073. View

13.

Pankuweit S, Ruppert V, Maisch B . Inflammation in dilated cardiomyopathy. Herz. 2004; 29(8):788-93. DOI: 10.1007/s00059-004-2626-9. View

14.

Coornaert B, Carpentier I, Beyaert R . A20: central gatekeeper in inflammation and immunity. J Biol Chem. 2008; 284(13):8217-21. PMC: 2659177. DOI: 10.1074/jbc.R800032200. View

15.

Trynka G, Zhernakova A, Romanos J, Franke L, Hunt K, Turner G . Coeliac disease-associated risk variants in TNFAIP3 and REL implicate altered NF-kappaB signalling. Gut. 2009; 58(8):1078-83. DOI: 10.1136/gut.2008.169052. View

16.

Badorff C, Fichtlscherer B, Rhoads R, Zeiher A, Muelsch A, Dimmeler S . Nitric oxide inhibits dystrophin proteolysis by coxsackieviral protease 2A through S-nitrosylation: A protective mechanism against enteroviral cardiomyopathy. Circulation. 2000; 102(18):2276-81. DOI: 10.1161/01.cir.102.18.2276. View

17.

Matsumori A, Nunokawa Y, Yamaki A, Yamamoto K, Hwang M, Miyamoto T . Suppression of cytokines and nitric oxide production, and protection against lethal endotoxemia and viral myocarditis by a new NF-kappaB inhibitor. Eur J Heart Fail. 2004; 6(2):137-44. DOI: 10.1016/j.ejheart.2003.10.007. View

18.

Yue Y, Gui J, Xu W, Xiong S . Gene therapy with CCL2 (MCP-1) mutant protects CVB3-induced myocarditis by compromising Th1 polarization. Mol Immunol. 2010; 48(4):706-13. DOI: 10.1016/j.molimm.2010.11.018. View

19.

Calabrese F, Thiene G . Myocarditis and inflammatory cardiomyopathy: microbiological and molecular biological aspects. Cardiovasc Res. 2003; 60(1):11-25. DOI: 10.1016/s0008-6363(03)00475-9. View

20.

Parvatiyar K, Harhaj E . Regulation of inflammatory and antiviral signaling by A20. Microbes Infect. 2010; 13(3):209-15. PMC: 3031767. DOI: 10.1016/j.micinf.2010.11.003. View